Name: Deltarasin
Price: 355.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    The KRAS oncogene product is considered a major target in anticancer drug discovery. Interfering with binding of mammalian PDEδ to KRAS by means of small molecules provides a novel opportunity to suppress oncogenic RAS signalling by altering its localization to endomembranes. Deltarasin is an inhibitor of the KRAS-PDEδ interaction to impair oncogenic KRAS signalling.
    In vitro: Within a minute, 5 mM of deltarasin completely inhibited PDEδ-KRAS interaction and released the insolubilized mCitrine-RHEB/KRAS6Q to the endomembrane system. This showed that deltarasin interfered with the binding of KRAS to PDEδ in cells and thereby inhibited its solubilization [1].
    In vivo: A clear dose-dependent reduction in Panc-Tu-I tumour growth rate could be observed in deltarasin treated mice with respect to the vehicle-injected controls, where the growth of tumours in mice that were treated with 10mg kg/1 BID deltarasin was almost completely blocked [1].
    Clinical trial: No clinical data are available.
- Properties
  - Alternative Name
    
    (S)-1-benzyl-2-(4-(2-(2-phenyl-1H-benzo[d]imidazol-1-yl)-2-(piperidin-4-yl)ethoxy)phenyl)-1H-benzo[d]imidazole
    
    CAS Number
    
    1440898-61-2
    
    Molecular Formula
    
    C40H37N5O
    
    Molecular Weight
    
    603.75
    
    Appearance
    
    White solid
    
    Purity
    
    98.00%
    
    Solubility
    
    Soluble in DMSO
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only